HIG1 hypoxia inducible domain family member 2AGenealiases: HIG2A · RCF1b
Q-omics provides the consensus-scored HIGD2A profile across patient tissues and cancer cell-line models. HIGD2A expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, HIGD2A is differentially expressed in 8, with the highest sampling consensus in KIRC. Additionally, HIGD2A protein abundance shows 18,850 significant protein co-abundance associations, with the highest sampling consensus in BRCA. Together, these results highlight MESO, KIRC, and BRCA as cancer lineages where HIGD2A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HIGD2A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HIGD2A survival associations across molecular data types. HIGD2A RNA expression shows survival associations in the most cancer types (24), followed by mutation status (1) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HIGD2A RNA expression–survival associations across cancer types. High HIGD2A expression shows unfavorable associations in KICH, LIHC, UCS, LUAD and ESCA, but favorable associations in MESO. The MESO Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for HIGD2A RNA expression.
This table summarizes HIGD2A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8, while mass-spec protein shows differences in 7. The strongest signals are observed in KIRC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for HIGD2A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HIGD2A shows lower tumor expression in BLCA and higher tumor expression in KIRC, LIHC, BRCA, CHOL and KIRP. The KIRC box plot shows higher HIGD2A RNA expression in tumor versus normal tissue (log2 FC = +0.463, t-test p < 0.001).
This table shows molecular features associated with HIGD2A in patient tissues and cancer cell lines. In patient samples, HIGD2A shows the broadest associations at the RNA and protein expression levels, with BRCA recurring as the lineage with the largest associated feature set. In cancer cell lines, HIGD2A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUSC and BLOOD_Leukemia.
